1005203-15-5 Usage
General Description
"S-1,3,4-Oxadiazole, 2-Methyl-5-[3-[4-(Methylsulfinyl)phenyl]-5-benzofuranyl]-" is a chemical compound with a complex molecular structure. It contains a 1,3,4-oxadiazole ring with a 2-methyl-5-[3-[4-(methylsulfinyl)phenyl]-5-benzofuranyl] side chain. s-1,3,4-Oxadiazole, 2-Methyl-5-[3-[4-(Methylsulfinyl)phenyl]-5-benzofuranyl]- is potentially important for pharmaceutical or agricultural applications due to its unique structure and properties. Further research and analysis of this chemical could uncover its potential benefits or applications in these and other fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1005203-15-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,5,2,0 and 3 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1005203-15:
(9*1)+(8*0)+(7*0)+(6*5)+(5*2)+(4*0)+(3*3)+(2*1)+(1*5)=65
65 % 10 = 5
So 1005203-15-5 is a valid CAS Registry Number.
1005203-15-5Relevant articles and documents
Enantioselective synthesis of the novel chiral sulfoxide derivative as a glycogen synthase kinase 3β inhibitor
Saitoh, Morihisa,Kunitomo, Jun,Kimura, Eiji,Yamano, Toru,Itoh, Fumio,Kori, Masakuni
experimental part, p. 1252 - 1254 (2010/11/04)
Glycogen synthase kinase 3β (GSK-3β) inhibitors are expected to be attractive therapeutic agents for the treatment of Alzheimer's disease (AD). Recently we discovered sulfoxides (S)-1 as a novel GSK-3β inhibitor having in vivo efficacy. We investigated practical asymmetric preparation methods for the scale-up synthesis of (S)-1. The highly enantioselective synthesis of (S)-1 (94% ee) was achieved by titanium-mediated oxidation with D-(-)-diethyl tartrate on gram scale.
